Key result
High systemic immune-inflammation index is linked to lower 3-year survival and predicts in-hospital mortality.
Why the study?
Inflammatory markers are associated with cardiovascular disease, but the predictive value of the novel systemic immune-inflammation index (SII) in STEMI patients was not established.
Does a high systemic immune-inflammation index predict worse in-hospital and long-term outcomes in patients with STEMI undergoing primary PCI?
Population
1660 STEMI patients undergoing primary PCI in a tertiary heart center
Comparison
High SII (Q3 and Q4) vs low SII (Q1)
Design
Cohort study
Follow-up
3 years
Authors
Loading...
Supports SII for risk stratification in STEMI PCI; hypothesis-generating and requires prospective validation before clinical use.
Cohort (n=1,660)
No
Does a high systemic immune-inflammation index predict worse in-hospital and long-term outcomes in patients with STEMI undergoing primary PCI?
Effect estimate: AUC 0.75 (95% CI 0.69-0.81)
p-value: p=<0.001
The systemic immune-inflammation index (SII) is a novel and effective predictor of in-hospital and long-term mortality and adverse events in STEMI patients undergoing primary PCI.
Öcal et al. (2021) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=1,660). Systemic immune-inflammation index (SII) vs. Low systemic immune-inflammation index (Q1) was evaluated on In-hospital mortality (AUC 0.75, 95% CI 0.69-0.81, p=<0.001). A high systemic immune-inflammation index predicted in-hospital mortality (AUC 0.75; 95% CI 0.69-0.81; p<0.001) and was associated with lower 3-year survival (81.0% in Q4 vs 97.6% in Q1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: